Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Hldg Ltd Spons (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 231,451,648
  • Shares Outstanding, K 6,815,420
  • Annual Sales, $ 53,441 M
  • Annual Income, $ 9,723 M
  • 36-Month Beta 0.82
  • Price/Sales 4.72
  • Price/Cash Flow 19.10
  • Price/Book 8.74
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/17
  • Annual Dividend & Yield 0.85 (2.46%)
  • Most Recent Dividend 0.84 on 03/15/17
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.5430 +4.35%
on 04/28/17
36.8200 -7.77%
on 04/28/17
+1.7600 (+5.47%)
since 04/26/17
3-Month
30.1900 +12.49%
on 02/27/17
36.8200 -7.77%
on 04/28/17
+3.3600 (+10.98%)
since 02/24/17
52-Week
25.2500 +34.50%
on 12/08/16
36.8200 -7.77%
on 04/28/17
+1.8400 (+5.73%)
since 05/26/16

Most Recent Stories

More News
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet

Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.

ALDX : 4.75 (unch)
VVUS : 1.13 (+0.89%)
ZTS : 62.61 (+0.05%)
RHHBY : 33.9600 (-1.19%)
Puma Soaring After Neratinib FDA Panel Win, Time to Buy?

Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast...

VVUS : 1.13 (+0.89%)
PBYI : 79.75 (+2.18%)
ZTS : 62.61 (+0.05%)
RHHBY : 33.9600 (-1.19%)
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

ALNY : 65.80 (-5.32%)
NVS : 80.63 (-0.89%)
RHHBY : 33.9600 (-1.19%)
SNY : 49.00 (-0.06%)
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

PUNE, India, May 22, 2017 /PRNewswire/ --

AUPH : 6.36 (-3.49%)
RHHBY : 33.9600 (-1.19%)
GSK : 42.67 (+0.23%)
BMY : 53.97 (-0.77%)
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

The report "Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)" analyses the development of this market, with focus on the U.S, Europe and Japan markets. The major trends, growth drivers...

AUPH : 6.36 (-3.49%)
RHHBY : 33.9600 (-1.19%)
GSK : 42.67 (+0.23%)
BMY : 53.97 (-0.77%)
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

AZN : 33.85 (-1.43%)
CLVS : 52.17 (-5.21%)
TSRO : 149.11 (-2.66%)
RHHBY : 33.9600 (-1.19%)
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

RHHBY : 33.9600 (-1.19%)
PFE : 32.14 (-0.06%)
MKGAF : 116.7400 (-0.11%)
BMY : 53.97 (-0.77%)
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

MRK : 64.92 (-0.18%)
IMDZ : 8.00 (-1.23%)
RHHBY : 33.9600 (-1.19%)
SNY : 49.00 (-0.06%)
Roche Holding Rises 1.52% on Heavy Volume: Watch For Potential Pullback

Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $34.13 to a high of $34.42. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of...

RHHBY : 33.9600 (-1.19%)
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).

AZN : 33.85 (-1.43%)
MRK : 64.92 (-0.18%)
RHHBY : 33.9600 (-1.19%)
BMY : 53.97 (-0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Support & Resistance

2nd Resistance Point 34.3667
1st Resistance Point 34.1633
Last Price 33.9600
1st Support Level 33.8533
2nd Support Level 33.7467

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.